TRSBF OTC

3SBio Inc. is a China-based investment holding company deeply engaged in the biopharmaceutical sector, encompassing the entire value chain from research and development to manufacturing, marketing, and sales of its innovative products. The company's extensive biopharmaceutical portfolio caters to a wide array of therapeutic needs. This includes treatments for various blood disorders like TPIAO (for chemotherapy-induced or immune thrombocytopenia), EPIAO and SEPO (recombinant erythropoietins for anemia), and SPARIN (a low-molecular-weight heparin for deep vein thrombosis prophylaxis and treatment, as well as for preventing clotting during hemodialysis), alongside Aiyishu for iron-deficiency anemia. Its autoimmune and inflammatory disease offerings feature YISAIPU, a tumor necrosis factor inhibitor effective against rheumatoid arthritis, ankylosing spondylitis, and psoriasis. In the oncology domain, 3SBio provides Cipterbin for HER2-positive metastatic breast cancer (in combination with chemotherapy), Intefen (a recombinant human interferon for lymphatic/hematopoietic malignancies and viral infections), and Inleusin (human interleukin-2 for renal cell carcinoma, melanoma, and thoracic fluid accumulation). Other specialized products address conditions such as male alopecia and alopecia areata (Mandi), acute rejection post-renal transplant (Xenopax), glycemic control in type 2 diabetes (Byetta), and diabetic retinopathy (Qiming Keli). In addition to its pharmaceutical operations, 3SBio diversifies its activities through services encompassing trading, project management, consulting, technology, and agriculture. The company has forged strategic collaboration agreements with a multitude of international partners, including prominent names like AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana-Farber Cancer Institute. Established in 1993, the company maintains its headquarters in Shenyang, China.